Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 1 / Phase 2interventionalRules rewrite

Phase 1 / Phase 2: testing ALN-2232 for Obesity

This study wants to: * measure the safety, tolerability, how well it works, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * measure the safety, tolerability, how well it works, PK, and PD of multiple doses of ALN-2232 in patients with obesity * measure the safety, tolerability, how well it works, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity

Official registry: https://clinicaltrials.gov/study/NCT07463846 · Alnylam Pharmaceuticals · enrollment listed as 156

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are ALN-2232, Placebo, or Tirzepatide. The registry lists allocation as randomized. This study wants to: * measure the safety, tolerability, how well it works, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * measure the safety, tolerability, how well it works, PK, and PD of multiple doses of ALN-2232 in patients with obesity * measure the safety, tolerability, how well it works, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity

They plan to enroll about 156 people at Mount Royal. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Adult Participants With Obesity

Interventions: ALN-2232, Placebo, Tirzepatide

Primary outcome (registry wording): Part A: Frequency of Adverse Events (AEs)

Who it is for (from inclusion criteria)

  • Ages 18 Years to 65 Years
  • Has a body mass index (body-mass index (BMI)) of ≥30 kg/m\^2 and \<40 kg/m\^2
  • Has a hemoglobin A1c (HbA1c) \<6.5%

Public study contact (from the registry)

Alnylam Clinical Trial Information Line

1-877-ALNYLAM

clinicaltrials@alnylam.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseSioux Falls, South Dakota
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

RecruitingNot a traditional drug phaseMontreal, Quebec
Not a traditional drug phase: Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE) for Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).

NCT03572465 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)

FAQ about this NCT record

Is NCT07463846 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07463846?

Phase 1 / Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07463846?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary